BRPI0308495B8 - composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto - Google Patents

composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto

Info

Publication number
BRPI0308495B8
BRPI0308495B8 BRPI0308495A BR0308495A BRPI0308495B8 BR PI0308495 B8 BRPI0308495 B8 BR PI0308495B8 BR PI0308495 A BRPI0308495 A BR PI0308495A BR 0308495 A BR0308495 A BR 0308495A BR PI0308495 B8 BRPI0308495 B8 BR PI0308495B8
Authority
BR
Brazil
Prior art keywords
alkyl
compound
hydrogen
cycloalkyl
substituted
Prior art date
Application number
BRPI0308495A
Other languages
English (en)
Other versions
BRPI0308495B1 (pt
BR0308495A (pt
Inventor
Ying Bai-Ping
Timothy Kohlman Daniel
Piatt Zacherl Deanna
Zhang Deyi
Victor Frantz
Philip Cohen Michael
Xi Liang Sidney
Mancuso Vincent
Xu Yao-Chang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308495A publication Critical patent/BR0308495A/pt
Publication of BRPI0308495B1 publication Critical patent/BRPI0308495B1/pt
Publication of BRPI0308495B8 publication Critical patent/BRPI0308495B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"composto, formulação farmacêutica, métodos para ativar receptores de 5-ht~ 1f~, para inibir o extravasamento de proteína neuronal, para tratar ou prevenir enxaqueca em um mamífero e papa preparar um composto, uso de um composto, e, processo para preparar um composto". a presente invenção refere-se aos compostos de fórmula i ou sais de adição de ácido farmaceuticamente aceitáveis dos mesmos, na qual r^ 1^ é c~ 1~-c~ 6~-alquila, c~ 1~-c~ 6~-alquila substituída, c~ 3~-c~ 7~ ciclo-alquila, c~ 3~-c~ 7~ cicloalquila substituída, c~ 3~-c~ 7~ ciclo-alquil-c~ 1~-c~ 3~-alquila, c~ 3~-c~ 7~ ciclo-alquil-c~ 1~-c~ 3~alquila substituída, fenila, fenila substituída, heterociclo, ou heterociclo substituído; r^ 2^ é hidrogênio, c~ 1~-c~ 3~-alquila, c~ 3~-c~ 6~ ciclo-alquil-c~ 1~-c~ 3~-alquila, ou um grupo de fórmula ii; r^ 3^ é hidrogênio ou c~ 1~-c~ 3~-alquila; r^ 4^ é hidrogênio, halo, ou c~ 1~c~ 3~-alquila; r^ 5^ é hidrogênio ou c~ 1~-c~ 3~-alquila, r^ 6^ é hidrogênio ou c~ 1~-c~ 6~-alquila; e n é um número inteiro de 1 a 6 inclusive. os compostos da presente invenção são úteis para a ativação de receptores de 5-htif, inibição de extravasamento de proteína neuronal, e para o tratamento ou a prevenção de enxaqueca em um mamífero. a presente invenção também se refere a um processo para a síntese de intermediários na sintese de compostos de fórmula i.
BRPI0308495A 2002-03-29 2003-03-27 composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto BRPI0308495B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36908802P 2002-03-29 2002-03-29
PCT/US2003/008455 WO2003084949A1 (en) 2002-03-29 2003-03-27 Pyridinoylpiperidines as 5-ht1f agonists

Publications (3)

Publication Number Publication Date
BR0308495A BR0308495A (pt) 2005-02-01
BRPI0308495B1 BRPI0308495B1 (pt) 2015-07-07
BRPI0308495B8 true BRPI0308495B8 (pt) 2021-05-25

Family

ID=28791923

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308495A BRPI0308495B8 (pt) 2002-03-29 2003-03-27 composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto

Country Status (32)

Country Link
US (6) US7423050B2 (pt)
EP (1) EP1492786B1 (pt)
JP (2) JP4493345B2 (pt)
KR (1) KR100985995B1 (pt)
CN (1) CN100352817C (pt)
AR (1) AR039150A1 (pt)
AT (1) ATE341543T1 (pt)
AU (1) AU2003224719B2 (pt)
BR (1) BRPI0308495B8 (pt)
CA (2) CA2478229C (pt)
CR (1) CR7496A (pt)
CY (1) CY1105899T1 (pt)
DE (1) DE60308850T2 (pt)
DK (1) DK1492786T3 (pt)
EA (1) EA007966B1 (pt)
EC (1) ECSP045317A (pt)
EG (1) EG25226A (pt)
ES (1) ES2277074T3 (pt)
HK (1) HK1073464A1 (pt)
HR (1) HRP20040883B1 (pt)
IL (1) IL163928A0 (pt)
MX (1) MXPA04009497A (pt)
MY (1) MY134666A (pt)
NO (1) NO330394B1 (pt)
NZ (1) NZ534952A (pt)
PE (1) PE20030976A1 (pt)
PL (1) PL210019B1 (pt)
PT (1) PT1492786E (pt)
TW (1) TWI263497B (pt)
UA (1) UA77504C2 (pt)
WO (1) WO2003084949A1 (pt)
ZA (1) ZA200407666B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
CN1777584A (zh) 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
JP2007516266A (ja) * 2003-12-17 2007-06-21 イーライ リリー アンド カンパニー ５−ｈｔ１ｆアゴニストとしての置換（４−アミノシクロヘキセン−１−イル）フェニルおよび（４−アミノシクロヘキセン−１−イル）ピリジニル化合物
WO2006022442A1 (ja) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
EP1794130A1 (en) * 2004-09-20 2007-06-13 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
US20060178349A1 (en) * 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EA200801108A1 (ru) * 2005-10-31 2008-10-30 Биолипокс Аб Триазолы, пригодные для лечения воспалений
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007052000A1 (en) * 2005-11-01 2007-05-10 Biolipox Ab Pyrazoles useful in the treatment of inflammation
RU2396265C2 (ru) * 2006-02-17 2010-08-10 Ф. Хоффманн-Ля Рош Аг Производные бензоилпиперидина в качестве модуляторов рецепторов 5ht2 и d3
CA2757019C (en) 2009-04-02 2018-05-15 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
US8429652B2 (en) 2009-06-22 2013-04-23 Citrix Systems, Inc. Systems and methods for spillover in a multi-core system
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
US20120129842A1 (en) 2010-11-18 2012-05-24 Paul Francis Jackson Bisthiazole inhibitors of pro-matrix metalloproteinase activation
CN102993086A (zh) * 2012-10-11 2013-03-27 南通市华峰化工有限责任公司 一种2，6-二溴吡啶的合成方法
WO2018010345A1 (zh) * 2016-07-15 2018-01-18 杭州领业医药科技有限公司 一种受体激动剂的晶型及其制备方法和药物组合物
KR20190066607A (ko) 2016-09-23 2019-06-13 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CN108137605B (zh) 2016-10-05 2021-07-13 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018085491A1 (en) * 2016-11-02 2018-05-11 Musc Foundation For Research Development 5ht1f receptor agonists and mitochondrial biogenesis
BR112019010934A2 (pt) * 2016-12-06 2019-10-01 Colucid Pharmaceuticals Inc composições e métodos relacionados a agonistas de piridinoilpiperidina 5-ht1f
JP7219091B2 (ja) * 2017-01-13 2023-02-07 住友ファーマ株式会社 パーキンソン病に伴う非運動症状の治療薬
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
SG11201908569QA (en) * 2017-03-21 2019-10-30 Arbutus Biopharma Corp Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
TWI754772B (zh) 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
CN110386918B (zh) * 2018-04-23 2020-06-09 新发药业有限公司 一种5-ht1f激动剂化合物的制备方法
CN110272425B (zh) * 2018-07-02 2022-11-04 广东东阳光药业有限公司 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
US11858910B2 (en) 2018-08-24 2024-01-02 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
WO2020095171A1 (en) * 2018-11-05 2020-05-14 Glenmark Life Sciences Limited, Glenmark Pharmaceuticals Limited Process for preparation of lasmiditan
ES2801774B2 (es) * 2019-07-01 2022-03-30 Moehs Iberica Sl 2,2-dimetil-n-[6-(1-metil-piperidin-4-carbonil)-piridin-2-il]-propionamida, procedimiento para la preparacion de (6-amino-piridin-2-il)-(1-metil-piperidin-4-il)-metanona usando dicho compuesto y uso de dicho compuesto en la preparacion de lasmiditan
TWI829107B (zh) * 2019-07-09 2024-01-11 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN110981854B (zh) * 2019-09-10 2023-03-28 南京三元阳普医药科技有限公司 2-氨基-6-(1-烷基哌啶-4-羰基)吡啶类化合物的合成方法
CN110845402B (zh) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 吡啶亚甲基哌嗪衍生物及其用途
CN111187251B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN111187252B (zh) * 2019-11-22 2023-06-09 广东东阳光药业有限公司 吡啶酰基氮杂螺庚烷衍生物及其用途
WO2021097781A1 (zh) * 2019-11-22 2021-05-27 广东东阳光药业有限公司 吡啶亚甲基哌啶衍生物及其用途
IT201900023937A1 (it) 2019-12-13 2021-06-13 Olon Spa Procedimento per la preparazione di Lasmiditan e di un intermedio di sintesi
CN113045540B (zh) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 一种拉司米地坦的制备方法
EP4096662A4 (en) * 2020-01-31 2024-02-14 Glenmark Life Sciences Limited PROCESS FOR PREPARING LASMIDITAN
CN113637003B (zh) * 2020-05-11 2024-03-19 鲁南制药集团股份有限公司 一种制备2-氨基-6-（哌啶-4-酰基）吡啶衍生物的方法
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
WO2022079591A1 (en) * 2020-10-14 2022-04-21 Alembic Pharmaceuticals Limited Pharmaceutical composition of lasmiditan and process of preparation thereof
US20240216356A1 (en) 2021-05-07 2024-07-04 Eli Lilly And Company Taste masked compostions of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and orally disentegrating tablet comprising the same
IT202100023861A1 (it) 2021-09-16 2023-03-16 Procos Spa Processo per la preparazione di (6-alopiridin-2-il)(1-metilpiperidin-4-il)metanone
CN113866318B (zh) * 2021-10-21 2023-07-04 佛山奕安赛医药科技有限公司 一种(6-氨基吡啶-2-基)(1-甲基哌啶-4-基)甲酮双盐酸盐的检测方法
WO2023152081A1 (en) 2022-02-09 2023-08-17 Inke, S.A. Process for preparing pyridinoylpiperidines 5-ht1f agonists and salts thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677428A (en) * 1900-04-28 1901-07-02 Chicago Handle Bar Co Steering device for bicycles.
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JPH03255426A (ja) 1990-03-06 1991-11-14 Toshiba Corp 有機非線形光学材料
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
US5360735A (en) 1992-01-08 1994-11-01 Synaptic Pharmaceutical Corporation DNA encoding a human 5-HT1F receptor, vectors, and host cells
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5698571A (en) 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CZ288897A3 (cs) 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6462048B2 (en) * 1996-03-29 2002-10-08 Pfizer Inc. Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-HT1A- and/or 5-HT1D receptors
US5708187A (en) 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
CA2264267A1 (en) 1996-08-28 1998-03-05 Michael Edward Flaugh Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta¬b|benzofurans
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
JP2001501946A (ja) 1996-10-08 2001-02-13 イーライ・リリー・アンド・カンパニー 新規セロトニン５―ｈｔ▲下１ｆ▼アゴニスト
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO2000000490A2 (en) 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
ATE252572T1 (de) * 1998-06-30 2003-11-15 Lilly Co Eli 5-ht1f agonisten
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
KR20010102003A (ko) * 1999-02-10 2001-11-15 피터 지. 스트링거 5-ｈｔ1ｆ 효능제
US6777428B1 (en) * 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
DE60008073T2 (de) 1999-02-26 2004-08-05 Eli Lilly And Co., Indianapolis Furo[3,2-b]pyridine als 5-ht1f agonisten
WO2002006196A1 (en) 2000-07-13 2002-01-24 Merck Patent Gmbh Chiral compounds i
US6650463B2 (en) 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US20050080112A1 (en) 2001-06-22 2005-04-14 Madsen Lars Siim Compounds for use in disorders associated with mast cell or basophil acitvity
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2004047739A2 (en) 2002-11-22 2004-06-10 Bristol-Myers Squibb Company Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
CN1777584A (zh) * 2003-04-18 2006-05-24 伊莱利利公司 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
UA82711C2 (en) 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
GB0510143D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
AU2005311251A1 (en) 2004-12-01 2006-06-08 Devgen Nv 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
KR20060067738A (ko) 2004-12-15 2006-06-20 주식회사 대웅제약 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 신규한 ｎ-아릴아마이드 유도체 및 이를함유하는 약제학적 조성물
US20060178349A1 (en) 2005-01-24 2006-08-10 Pozen Inc. Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
CA2757019C (en) 2009-04-02 2018-05-15 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists

Also Published As

Publication number Publication date
US20080300407A1 (en) 2008-12-04
JP2005530722A (ja) 2005-10-13
NZ534952A (en) 2005-11-25
HRP20040883A2 (en) 2004-12-31
DE60308850T2 (de) 2007-05-24
EA200401282A1 (ru) 2005-02-24
NO20044654L (no) 2004-10-28
MY134666A (en) 2007-12-31
TWI263497B (en) 2006-10-11
KR20040094872A (ko) 2004-11-10
US20150376178A1 (en) 2015-12-31
US20120329820A1 (en) 2012-12-27
US8044207B2 (en) 2011-10-25
MXPA04009497A (es) 2005-06-08
TW200306186A (en) 2003-11-16
NO330394B1 (no) 2011-04-04
CA2694410A1 (en) 2003-10-16
AU2003224719B2 (en) 2008-08-14
HRP20040883B1 (en) 2012-11-30
IL163928A0 (en) 2005-12-18
WO2003084949A1 (en) 2003-10-16
CA2694410C (en) 2013-01-29
CY1105899T1 (el) 2011-02-02
HK1073464A1 (en) 2005-10-07
CA2478229C (en) 2011-03-22
PL210019B1 (pl) 2011-11-30
ECSP045317A (es) 2004-11-26
US20090209563A1 (en) 2009-08-20
PL372845A1 (en) 2005-08-08
PE20030976A1 (es) 2003-11-12
JP2010159272A (ja) 2010-07-22
BRPI0308495B1 (pt) 2015-07-07
ATE341543T1 (de) 2006-10-15
AU2003224719A1 (en) 2003-10-20
DE60308850D1 (de) 2006-11-16
JP4493345B2 (ja) 2010-06-30
AR039150A1 (es) 2005-02-09
CR7496A (es) 2004-11-27
US20050222206A1 (en) 2005-10-06
PT1492786E (pt) 2007-01-31
ZA200407666B (en) 2006-02-22
KR100985995B1 (ko) 2010-10-06
CA2478229A1 (en) 2003-10-16
ES2277074T3 (es) 2007-07-01
DK1492786T3 (da) 2007-02-12
EP1492786B1 (en) 2006-10-04
CN100352817C (zh) 2007-12-05
US20170044136A1 (en) 2017-02-16
US7423050B2 (en) 2008-09-09
CN1642939A (zh) 2005-07-20
EG25226A (en) 2011-11-17
EA007966B1 (ru) 2007-02-27
BR0308495A (pt) 2005-02-01
EP1492786A1 (en) 2005-01-05
UA77504C2 (en) 2006-12-15
US8748459B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
BRPI0308495B8 (pt) composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto
BRPI0409211A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f, para inibir extravasão de proteìna neuronial, e para o tratamento ou prevenção de enxaqueca em um mamìfero, e, uso de um composto
BR9810829A (pt) Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
BRPI0507499A (pt) composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
BRPI0409227B8 (pt) &#34;composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)&#34;
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BR0201437A (pt) Processo para preparar derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4&#34;-substituìdos&#34;
BR0211122A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
DE60212836D1 (de) Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
BRPI9913542B8 (pt) derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BRPI0414177A (pt) inibidores de girase
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0414738A (pt) derivados de ácido acético substituìdos
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
BR0315056A (pt) Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
BRPI0508825A (pt) compostos derivados de benzil (ideno)-lactama, suas composições farmacêuticas e processos para suas preparações
BRPI0414241A (pt) composto, composição farmacêutica, métodos para ativar receptores 5-ht1f em um mamìfero, para inibir o extravasamento de proteìna neuronal em um mamìfero e para tratar ou prevenir enxaqueca em um mamìfero, e, uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27/03/2023